Bris­tol My­ers touts PhI­II Op­di­vo win in urothe­lial car­ci­no­ma; Lim­i­nal Bio­Sciences goes pri­vate

Bris­tol My­ers Squibb said Tues­day that a sub-study of a Phase III tri­al test­ing Op­di­vo with cis­platin-based chemother­a­py, fol­lowed by Op­di­vo monother­a­py, met the pri­ma­ry …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.